Pre-market Hot Trades in US Stocks
Intel is down 4.08% in pre-market trading. Based on recent key news:
<ol>
<li>
On May 12, Intel's stock price fell due to valuation pressure. Despite strong market sentiment, Wall Street analysts are not optimistic about Intel's stock, with a target price indicating about a 34% downside from the current price. Source: Bloomberg
</li>
<li>
On May 13, rumors about Intel's foundry business drove the stock price up. The market expects Intel to collaborate with Apple and SK Hynix, and Deutsche Bank raised the target price to $100. Source: The Wall Street Journal
</li>
<li>
On May 14, Intel's Q1 earnings report exceeded expectations, leading analysts to raise their target prices. The company's revenue and earnings both surpassed expectations, driving the stock price up. Source: Stock Analysis. The chip industry is under valuation pressure, with significant capital inflows.
</li>
</ol>
BHP is down 3.90% in pre-market trading. Based on recent key news:
<ol>
<li>
On May 14, the production of coking coal in Australia is struggling to maintain recovery, affecting the tightness of the metallurgical coal market. The Goonyella Riverside project, a joint venture between BHP and Mitsubishi Corporation, failed to restore production, leading to tight market supply and supporting coal prices. Source: Jin10 Data
</li>
<li>
On May 15, Morgan Stanley raised BHP's target stock price by 17% to AUD 67.50 per share. This move reflects market confidence in BHP's future growth and may have a positive impact on the stock price. Source: Morgan Stanley
</li>
<li>
On May 13, BHP's copper production accounted for 51% of the group's EBITDA, with copper production growing by about 30% over four years. This growth was driven by the Oz Minerals transaction, improvements at Escondida, and development at Vicuna, demonstrating the company's strong position in the copper market. Source: Dow Jones Newswires. Strong copper demand and market tightness require attention to risks.
</li>
</ol>
Top Gainers in Pre-market US Stocks
HCW Biologics is up 144.36% in pre-market trading. Based on recent key news:
<ol>
<li>
On May 14, HCW Biologics announced that its candidate drug HCW11-040 showed effectiveness in preventing bronchopulmonary dysplasia in IND-enabled studies. This news boosted investor confidence in the company's future research outcomes, leading to a significant rise in stock price. Source: Reuters
</li>
<li>
On May 14, HCW Biologics released its Q1 2026 earnings report, showing progress in its innovative immunotherapy business and financial data. The positive performance of the earnings report further enhanced market confidence in the company. Source: Company Announcement
</li>
<li>
On May 15, analysts rated HCW Biologics as &#34;Buy,&#34; predicting a 12-month price target of $2.00, which is 472.4% higher than the closing price of $0.35 on May 13. This optimistic analyst expectation provides strong support for the stock price
Source: Reuters The biotechnology industry has recently shown active performance, with significant capital inflows.
</li>
</ol>
Dreamland pre-market rose 96.25%. Based on recent key news:
<ol>
<li>
On May 12, Dreamland signed a memorandum of understanding with LinkFung Innovation to develop an AI-driven smart image library platform. This collaboration is expected to expand market influence and drive profit growth, resulting in a rise in stock price.
</li>
<li>
On May 13, Dreamland's stock price surged 126.92%, with a transaction amount of approximately $219 million, indicating an extremely rare scale of capital inflow. Technical indicators show bullish signals, but further dimensions need to be considered, as stock price fluctuations are severe.
</li>
<li>
On May 14, technical analysis showed that the RSI reached 97.75, indicating that the stock price is extremely overbought and may face severe correction risks. The stock price is far above key moving averages, and market sentiment is highly optimistic. There have been no significant positive developments in the film and entertainment industry recently.
</li>
</ol>
Auddia pre-market rose 62.28%. Based on recent key news:
<ol>
<li>
On May 15, Auddia submitted an S-4 filing to merge with Thramann Holdings, establishing McCarthy Finney as a unified AI platform. This move is seen as an important step in the company's strategic expansion, driving a significant rise in stock price. Source: Reuters
</li>
<li>
On May 12, the management of Auddia and Thramann Holdings was believed to be involved in a proxy solicitation related to the company's merger affairs. This information increased market confidence in the success of the merger, further stimulating the rise in stock price. Source: Auddia Inc.
</li>
<li>
On May 15, investor relations documents showed that Auddia's merger plan received positive feedback, with market expectations that the merger will bring significant synergies, driving the stock price up. Source: PCG Advisory, Inc. The trend of consolidation in the AI industry is evident, with accelerated capital inflows
</li>
</ol>

INTC

Intel pre-market down 4.08%; BHP pre-market down 3.90%; HCW Biologics pre-market up 144.36%; Dreamland pre-market up 96.25%; Auddia pre-market up 62.28%

- Intel's stock fell 4.08% pre-market due to valuation pressures despite a positive earnings report and rumors of collaborations with Apple and SK Hynix.  
- BHP's shares also dropped 3.90% as production issues at a key coal project affected supply, although Morgan Stanley raised their price target by 17%.  
- Meanwhile, HCW Biologics surged 144.36% after promising trial results for its drug candidate, while Auddia saw a 62.28% rise following a merger announcement with Thramann Holdings.

Price Alert

Pre-market hot trades in US stocks: Intel pre-market down 4.08%; BHP pre-market down 3.90%